Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
28,650
datasets available to search
ShareScore release 0.9.0
Dataset results
28,650 results for “trial”
HOSENG trial – HOme-based oral SElf-testiNG for absent and refusing individuals during a door-to-door HIV testing campaign: a cluster randomised clinical trial in rural Lesotho
<p>These are pseudo-anonymised data from the HOSENG randomized trial: " HOSENG trial – HOme-based oral SElf-testiNG for absent and refusing individuals during a door-to-door HIV testing campaign: a cluster randomised clinical trial in rural Lesotho". The data dictionary explains the data available in the dataset. Between July 2018 and December 2018, 10516 eligible individuals from 106 consenting villages were enrolled from two districts of Lesotho, and followed up for a maximum of 120 days. Main manuscript reference, DOI: <a href="https://doi.org/10.1016/s2352-3018(20)30233-2">10.1016/S2352-3018(20)30233-2. </a>The protocol was published, DOI:10.1186/s13063-019-3469-2.</p>
S3 | NORMANCT15 | NORMAN Collaborative Trial Targets and Suspects
<p>This is the collection associated with list S3 NORMANCT15 on the NORMAN Suspect List Exchange.</p> <p><a href="https://www.norman-network.com/nds/SLE/">https://www.norman-network.com/nds/SLE/</a></p> <p>S3 | NORMANCT15 | <strong>NORMAN Collaborative Trial Targets and Suspects</strong></p> <p>Schymanski <em>et al</em>. 2015.<br>DOI: <a href="http://link.springer.com/article/10.1007/s00216-015-8681-7">10.1007/s00216-015-8681-7</a></p> <p>Upload 22/3/2020: added merged InChIKey file for PubChem data extraction. 27/6/2025: added merged CSV</p>
Another-Trial-of-Depositor-0003
<p>This deposition is best described in the following terms... extending the sentence here, just so that it is obvious that one can add paragraph(s) of text.</p>
Dataset: Seasonal field trials of single-seed removal by desert birds from experimental devices in Ñacuñan Reserve (Mendoza, Argentina)
<p>Dataset for the paper: Milesi FA, Lopez de Casenave J & Cueto VR (2018) Which food patches are worth exploring? Foraging desert birds do not follow environmental indicators of seed abundance at small scales: a field experiment. bioRxiv 295923. doi: https://doi.org/10.1101/295923</p> <p>Metadata included within the tab-delimited text file</p>
Dataset for the IntoValue 1 + 2 studies on results dissemination from clinical trials conducted at German university medical centers completed between 2009 and 2017
<p>The IntoValue dataset contains clinical trials conducted at one of 35 German UMCs and registered on ClinicalTrials.gov or the German Clinical Trials Registry (DRKS). All trials were reported as complete between 2009 and 2017 on the trial registry at the time of data collection. The dataset also includes a results publication found via manual searches; if multiple results publications were found, the earliest was included.</p> <p>Trials were associated with a German UMC by searching for trials with a UMC listed as responsible party or lead sponsor, or with a principle investigator (PI) from a UMC ('lead_city'). Version 1 additionally includes trials with a UMC only as a facility (`facility_city`). A lookup table of regular expressions used to identify German UMCs is available at <a href="https://github.com/quest-bih/IntoValue2/blob/master/data/1_sample_generation/city_search_terms.csv">https://github.com/quest-bih/IntoValue2/blob/master/data/1_sample_generation/city_search_terms.csv</a>.</p> <p>Trials include all interventional studies and are not limited to investigational medical product trials, as regulated by the EU's Clinical Trials Directive or Germany's Arzneimittelgesetz (AMG) or Novelle des Medizinproduktegesetzes (MPG).</p> <p>DRKS data were searched (pre-filtered for completion years and study status as well as Germany as 'Country of recruitment') and downloaded as CSVs from the DRKS website (<a href="https://www.drks.de/">https://www.drks.de/</a>). ClinicalTrials.gov data were downloaded downloaded as pipe files from Clinical Trials Transformation Initiative (CTTI) Aggregate Content of ClinicalTrials.gov (AACT) (<a href="https://aact.ctti-clinicaltrials.org/pipe_files">https://aact.ctti-clinicaltrials.org/pipe_files</a>). DRKS and ClinicalTrials.gov use different terminology for various trial aspects, such as phase and masking; these different levels are captured in the data dictionary as `levels_drks` and `levels_ctgov`. For later analyses requiring parity across registries, levels for some variables were collapsed and a lookup table is provided in `iv_data_lookup_registries.csv`.</p> <p>These data were generated and used for two publications (Wieschowski et al., 2019; Riedel et al. 2021) and therefore comprises two versions (indicated as `iv_version`).</p> <p>For version 1, registry data was collected on April 17, 2017 from ClinicalTrials.gov and on July 27, 2017 for DRKS and was limited to trials with a completion date on DRKS and primary completion date on ClinicalTrials.gov between 2009 and 2013. Version 1 manual searches for results publications were conducted from 2017-07-01 to 2017-12-01.<br> For version 2, registry data was collected on June 3, 2020 and was limited to trials with a completion date on DRKS and ClinicalTrials.gov between 2014 and 2017. Version 2 manual searches for results publications were conducted from 2020-07-01 to 2020-09-01.</p> <p>Raw registry data for versions 1 and 2 is available in `raw-registries.zip`.</p> <p>Publication identifiers (DOI, PMID, URL) were manually entered during the publication search and then further enhanced using the API of Internet Archive's open-source Fatcat catalog of research publications, to add PMIDs based on DOIs, and vice versa.</p> <p>Manual search steps differed slightly in the two versions and are indicated and described in `identification_step`.<br> Version 1 includes trials with a German UMC as either a `lead_city` or a `facility_city`, whereas version 2 is limited to trials a German UMC as a `lead_city`.</p> <p>Each row indicates a single trial registration. Due to changes in completion dates, some trials are duplicated between versions as indicated in `is_dupe`. Cross-registered trials were manually deduplicated, and some cross-registered duplicates remain (e.g., DRKS00004156 and NCT00215683) and are not indicated in the dataset.</p> <p>All dates are provided as `yyyy-mm-dd`.</p> <p>Additional documentation on each variable (type, description, levels) is provided in `iv_data_dictionary.csv`.</p> <p>Additional information on the project and methods for generating the dataset is available in associated publications and at the project's OSF page (<a href="https://osf.io/98j7u/">https://osf.io/98j7u/</a>). Code for the project is available at <a href="https://github.com/quest-bih/IntoValue2">https://github.com/quest-bih/IntoValue2</a>.</p> <p><strong>References:</strong></p> <p>Wieschowski, S., Riedel, N., Wollmann, K., Kahrass, H., Müller-Ohlraun, S., Schürmann, C., Kelley, S., Kszuk, U., Siegerink, B., Dirnagl, U., Meerpohl, J., & Strech, D. (2019). Result dissemination from clinical trials conducted at German university medical centers was delayed and incomplete. Journal of Clinical Epidemiology, 115, 37–45. <a href="https://doi.org/10.1016/j.jclinepi.2019.06.002">https://doi.org/10.1016/j.jclinepi.2019.06.002</a></p> <p>Riedel, N., Wieschowski, S., Bruckner, T., Holst, M. R., Kahrass, H., Nury, E., Meerpohl, J. J., Salholz-Hillel, M., & Strech, D. (2021). Results dissemination from completed clinical trials conducted at German university medical centers remained delayed and incomplete. The 2014-2017 cohort. Journal of Clinical Epidemiology, 0(0). <a href="http://doi.org/10.1016/j.jclinepi.2021.12.012">https://doi.org/10.1016/j.jclinepi.2021.12.012</a><br> </p>
City of Seattle, Seattle Public Utilities, Restoration Thinning Trial, 2005 - 2017, Cedar River Municipal Watershed, King County, WA
The Restoration Thinning (RT) Program in the Cedar River Municipal Watershed (CRMW) was one of three forest restoration programs (the others being Ecological Thinning and Planting) defined and funded through the Cedar River Watershed Habitat Conservation Plan (HCP) that was signed and initiated in April of 2000. Restoration thinning and ecological thinning projects were combined into the 'Upland Forest Thinning' project and are ongoing today to meet objectives outlined in the Habitat Conservation Plan and Forest Managment Plan. The primary goal of the RT program, which is analogous to pre-commercial thinning, was to actively thin dense young second-growth forest stands (generally less than 30 years old) to facilitate ecological development towards old-growth forest habitat conditions. Objectives of RT include: Reduce competition among trees. Stimulate tree growth. Increase light penetration under the top tree canopy. Increase tree and understory plant species diversity. Accelerate forest development beyond the competitive exclusion stage towards a more biologically diverse stage. Extend the forest development stand initiation stage such that diverse species become established and diverse stand structures develop. Provide multiple development pathways for variable forest stand structures. Reduce long-term fire hazard. Increase resilience to catastrophic windthrow, insect, or disease outbreak. Increase habitat connectivity and structural variability of riparian areas. This data package describes a forest restoration trial in young conifer forests of the western central Cascade Range in Washington State, USA. Young second-growth forests often regenerate as very dense, homogeneous stands following harvesting. These forests have low species diversity and trees often experience strong competition for resources. To increase tree vigor and growth and stimulate development of diverse understory, shrub species stands are thinned with the long-term goal to restore diverse func
Cardiorespiratory metrics of cobia during and following a Ucrit trial upon a 3 wk exposure to either ambient or elevated pCO2
This study examined cardiac and swimming performance during a maximum sustained swimming trial (Ucrit) of cobia (Rachycentron canadum) following a three-week exposure to either elevated (~1,600 µAtm) or ambient (~500 µAtm) pCO₂. This dataset encompasses cardiac variables (stroke volume, heart rate, and cardiac output) during swimming and recovery from a Ucrit trial, hematological variables (hemoglobin, hematocrit, mean corpuscular hemoglobin concentration) following the swimming test and hour long recovery, oxygen consumption variables (MO₂ min, MO₂ max, aerobic scope, and factorial aerobic scope) during and following the swimming test.
Inter-Chemical Correlation results for the study: HHEARx2017-1967 (Perfluoroalkyl and Polyfluroalkyl Substances (PFAS), Protein Biomarkers, Adiposity and Cardiometabolic Risk Factors in a 3-year Cohort of Low-Income Latino Children with Overweight and Obesity from the Stanford GOALS Randomized Controlled Trial)
Title: Perfluoroalkyl and Polyfluroalkyl Substances (PFAS), Protein Biomarkers, Adiposity and Cardiometabolic Risk Factors in a 3-year Cohort of Low-Income Latino Children with Overweight and Obesity from the Stanford GOALS Randomized Controlled Trial <br>Species: Homo sapiens <br>Number of samples: 1085 <br>Number of named analytes: 8 <br>Datasource url: https://hheardatacenter.mssm.edu/PublicFile/ViewPublicFile?projectid=36 <br>
DATA SET: Performance Assessment of a Commercial Continuous-Wave Near-Infrared Spectroscopy Tissue Oximeter for Suitability for Use in an International, Multi-Center Clinical Trial
<p>This repository contains the data sets related to the publication:</p> <p>Cortese, L.; Zanoletti, M.; Karadeniz, U.; Pagliazzi, M.; Yaqub, M.A.; Busch, D.R.; Mesquida, J.; Durduran, T. Performance Assessment of a Commercial Continuous-Wave Near-Infrared Spectroscopy Tissue Oximeter for Suitability for Use in an International, Multi-Center Clinical Trial. <em>Sensors</em> <strong>2021</strong>, <em>21</em>, 6957. https://doi.org/10.3390/s21216957</p>
S35 | INDOORCT16 | Indoor Environment Substances from 2016 Collaborative Trial
<p>This is the collection associated with list S35 INDOORCT16 on the NORMAN Suspect List Exchange.</p> <p><a href="https://www.norman-network.com/nds/SLE/">https://www.norman-network.com/nds/SLE/</a></p> <p>S35 INDOORCT16 <strong>Indoor Environment Substances from 2016 Collaborative Trial</strong></p> <p>Lists of GC-MS and LC-MS compounds and DSFP output, plus merged files from the Indoor Dust Collaborative Trial, 2016 provided by Peter Haglund (UMU) and Pawel Rostkowski (NILU). Details in Rostkowski <em>et al</em>. 2019 DOI: <a href="https://link.springer.com/article/10.1007/s00216-019-01615-6">10.1007/s00216-019-01615-6</a></p> <p>Update 6 Feb 2020: two NA SMILES removed in CSV for PubChem upload. 17/7/2022: NA and N/A SMILES removed from CSV and XLSX, most replaced with structures; some are representative structures for classes.</p>
MiRoR11 - P2 - Annotated corpus for semantic similarity of clinical trial outcomes
<p>Outcome similarity corpus</p> <p>This dataset contains annotations of semantic similarity for pairs of primary and reported outcomes.<br> Tab-separated format is used. The files contain the following columns:<br> filename, sentence pair ID, sentence pair text, primary outcome, primary outcome start position, primary outcome end position, reported outcome, reported outcome start position, reported outcome end position, label</p> <p>The folder out_relations_split contains the dataset splits for 10-fold cross-validation.</p>
Post-trial access practice in Malaria, Tuberculosis, and NTDs Clinical Trial studies in Sub-Saharan African countries, quantitative study
<p>This is the data set used <span>to evaluate post trial access plan and implementation practice on TB, Malaria and NTD clinical trial studies conducted in the sub-Saharan African countries. </span></p>
Offering ART refill through community health workers versus clinic-based follow-up after home-based same-day ART initiation in rural Lesotho: The VIBRA cluster-randomised clinical trial
<p>These are pseudo-anonymised data from the VIBRA randomized trial: "Offering ART refill through community health workers versus clinic-based follow-up after home-based same-day ART initiation in rural Lesotho: The VIBRA cluster-randomised clinical trial". The data dictionary explains the data available in the dataset. Between August 2018 and May 2019, 257 eligible individuals from 117 consenting villages were enrolled from two districts of Lesotho, and followed up for a maximum of 15 months. The protocol was published, doi: 10.1186/s13063-019-3510-5</p>
TomoBreast randomized clinical trial's lung-heart outcomes and mortality through the 2020 COVID-19 pandemic: data and software
<p>Dataset and R script to reproduce the analyses of the manuscript:</p> <p>Vinh-Hung V, Gorobets O, Adriaenssens N, Van Parijs H, Storme G, Verellen D, Nguyen NP, Magne N, De Ridder M.</p> <p><strong>Lung-heart outcomes and mortality through the 2020 COVID-19 pandemic in a prospective cohort of breast cancer radiotherapy patients.</strong></p> <p>Cancers 2022; 14(24):6241. https:// doi.org/10.3390/cancers14246241</p> <p>https://www.mdpi.com/2072-6694/14/24/6241</p> <p>PubMed: PMID: 36551726</p> <p>PMCID: PMC9777311</p> <p>Info on the variables in file "aelq6_public.R"</p> <p>reproduced in "aelq_2_3_readme.txt":</p> <p>"aelq2_base2.txt" = baseline characteristics.</p> <p>"aelq3.txt" = longitudinal maesurements.</p> <p>Variables in "aelq2_base2.txt":</p> <p>"<strong>aelq2_base2.txt</strong>" = baseline characteristics. <br># Age at randomization, years. <br># RTdose: cf TomoBreast papers. <br># 51 Gy = hypofractionated, simultaneous integrated boost<br># 42 Gy = hypofractionated, no boost, mastectomy cases only<br># 50 Gy = conventional, no boost, mastectomy cases only<br># 66 Gy = conventional, sequential boost<br># Weight kg, Height cm, <br># Detection 1=found by screening (senology follow-up/controle)<br># 2=found by symptoms (pain, palpable)<br># 9=unknown<br># Smoker 0= Not smoker<br># 1= Smoker<br># 2=ex-smoker<br># Mastectomy (and other binary coded) 1= yes<br># chemosched 0=none<br># 1= planned after RT (sequential)<br># 2= prior to RT and is finished (sequential)<br># 3= chemo is on-going or is planned to start with RT (concomitant)<br># hormonetherapy 0=no<br># 1=tamoxifen (nolvadex)<br># 2=Femara (Letrozole)<br># 3=zoladex<br># 4=tamoxifen + zoladex<br># Laterality 1,=Right, 2=Left, 3=Bilateral<br># LengthFU: length of follow-up, days from randomization</p> <p>"<strong>aelq3.txt</strong>" = longitudinal maesurements.<br># "Nr" = Case ID<br># "Time" in days from origin (origin =date of randomization), <br># if negative =before randomization<br># "KPS" "Weight" <br># "Died" "LocalRec" "Metast" "NewPrim" = binary code, 0=no, 1=yes<br># "fAEBreast" "fAEHeart" "fAELung" "fAEOther" <br># fAE = freedom from breast, heart, lung, other adverse event score<br># "LVEF2" = ejection fraction, %<br># "MacIver" = estimated cardiac strain</p> <p># the following are pulmonary function tests, untransformed units<br># "FVC", "FEV1", "PEF", "VC", "TLC", "RV", "FRC", "Raw", "sRaw", "DLCO",<br># "VA", "PF"</p> <p># "fDY", "fFA", "fPA" = freedom from dyspnea, from fatigue, from pain<br># range 0 to 100 (best)<br># see papers:</p> <p># Van Parijs, H.; Vinh-Hung, V.; Fontaine, C.; Storme, G.; Verschraegen, C.;<br># Nguyen, D.M.; Adriaenssens, N.; Nguyen, N.P.; Gorobets, O.; De Ridder, M.<br># Cardiopulmonary-related patient-reported outcomes in a randomized clinical<br># trial of radiation therapy for breast cancer. BMC Cancer 2021, 21, 1177,<br># doi:10.1186/s12885-021-08916-z.</p> <p># preprint:<br># Van Parijs, H.; Cecilia-Joseph, E.; Gorobets, O.; Storme, G.; <br># Adriaenssens, N.; Heyndrickx, B.; Verschraegen, C.; Nguyen, N.P.;<br># De Ridder, M.; Vinh-Hung, V. Lung-heart toxicity in a randomized <br># clinical trial of hypofractionated image guided radiation therapy for<br># breast cancer. Preprints 2022, 202212, 0214.<br># https://doi.org/10.20944/preprints202212.0214.v1</p> <p># <br># "Year" = year of the observation<br># example: randomized 1/1/2011, measurement done 1/31/2011, time = 30 days,<br># Year =2011<br>#<br> </p>
Dataset Treatment of early childhood caries with three different topical fluoride treatments: a randomised clinical trial
<p>These files contain the data and the research script about the effectiveness of the 38% silver diamine fluoride (SDF, SDI Riva Star) and Tiefenfluorid (TF, Humanchemie GmbH), using two different application protocols in children ≤71 months of age with early childhood caries, with a focus on patient-centred outcomes including major complications (pain, abscess, extraction) and minor complications (lesion progression).</p> <p>This work was funded by European Regional Development Fund Postdoc Latvia 1.1.1.2/VIAA/3/19/543, Contract No 9.-14.5/27. Uribe was supported by European Union’s Horizon 2020 grant agreement 857287 for the Baltic Biomaterials Centre of Excellence.</p>
Datasets of fitted toy Monte Carlo samples for "Gaussian Process-based calculation of look-elsewhere trials factor"
<p>For the paper "Gaussian Process-based calculation of look-elsewhere trials factor", we generated and fitted a number of toy Monte Carlo samples which can be used to reproduce figures from the paper or do tests of hypotheses inspired by the method suggested in the article.</p> <p>Together with the hdf5 files containing the samples, we also provide a Jupyter notebook which was used to produce the figures.</p>
First Steps towards a Risk of Bias Corpus of Randomized Controlled Trials
<p><strong>Abstract</strong></p> <p>Risk of bias (RoB) assessment of randomized clinical trials (RCTs) is vital to conducting systematic reviews. Manual RoB assessment for hundreds of RCTs is a cognitively demanding, lengthy process and is prone to subjective judgment. Supervised machine learning (ML) can help to accelerate this process but requires a hand-labelled corpus. There are currently no RoB annotation guidelines for randomized clinical trials or annotated corpora. In this pilot project, we test the practicality of directly using the revised Cochrane RoB 2.0 guidelines for developing an RoB annotated corpus using a novel multi-level annotation scheme. We report inter-annotator agreement among four annotators who used Cochrane RoB 2.0 guidelines. The agreement ranges between 0% for some bias classes and 76% for others. Finally, we discuss the shortcomings of this direct translation of annotation guidelines and scheme and suggest approaches to improve them to obtain an RoB annotated corpus suitable for ML.</p> <p> </p> <p><strong>Methods</strong></p> <p>The upload contains two zip files and a .json file.</p> <ul> <li>plain.html.zip</li> </ul> <p>Original corpus (n = 10) in .html format. The corpus was generated using the methodology described in the paper. Each .html file could be opened in any default text editor in any operating system or browser. A .html contains full text divided into several annotatable text parts. </p> <p> </p> <ul> <li>ann.json.zip</li> </ul> <p>The .zip contains RoB annotations conducted by the authors (R.H., M.S., K.G., R.C.). The annotation files are in .json format. Each .json is divided into two JSON objects and three JSON arrays. </p> <ol> <li>annotatable (object): Parts from the full-text document corresponding to the text parts from the plain .html files. </li> <li>metas (object): full-text document label</li> <li>entities (array): contains labelled entities. Each entity is linked to which part of the full-text it is linked to.</li> <li>relations (array)</li> <li>sources (array)</li> </ol> <p> </p> <ul> <li>annotations-legend.json</li> </ul> <p>This .json file contains entity and entity labels encoded to text legends. For example, entity class label "1_2_Yes_Good" is encoded as "e_113".</p> <p> </p> <p><strong>Resources</strong></p> <p>The code to parse annotations can be found on <a href="http:// https://github.com/anjani-dhrangadhariya">GitHub</a>.</p> <p> </p> <p><strong>Funding</strong></p> <p>HES-SO Valais-Wallis, Sierre, Switzerland</p>
Final Dataset for the DIssemination of REgistered COVID-19 Clinical Trials (DIRECCT) Study
<p>The DIRECCT study is a multi-phase examination of clinical trial results dissemination during the COVID-19 pandemic.</p> <p>Interim data for trials completed during the first six months of the pandemic (i.e., 1 January 2020 – 30 June 2020) was previously deposited at https://doi.org/10.5281/zenodo.4669936.<br> This data deposit comprises the results of searches for trials completed during the first 18-months of the pandemic (i.e., 1 January 2020 – 30 June 2021).<br> The data structure for the final phase of the project is not identical to the interim data as it was substantially more complex.<br> The data include datatables (CSVs) that can be treated as relational and joined on the `id` or `trn` columns. See datamodel.png for an overview of the data.</p> <p>Details on data sources and methods for the creation and analysis of this dataset are available in a detailed protocol (Version 3.1, 19 July 2023) : https://osf.io/w8t7r</p> <p>Note: This repository will be updated with additional information including a codebook and archives of raw data.</p> <p>Additional information on the project is available at the project's OSF page: https://doi.org/10.17605/osf.io/5f8j2.</p>
DICOM converted whole slide hematoxylin and eosin images of rhabdomyosarcoma from Children's Oncology Group trials
<p>Rhabdomyosarcoma (RMS) is an aggressive soft-tissue sarcoma, which primarily occurs in children and young adults. This dataset contains manifests referring to the hematoxylin and eosin (H&E) stained images in Digital Imaging and Communications in Medicine (DICOM) format available from National Cancer Institute Imaging Data Commons (IDC) [1] (also see IDC Portal at <a href="https://imaging.datacommons.cancer.gov">https://imaging.datacommons.cancer.gov</a>) as of data release v16. The original images in vendor-specific format were collected on IRB-approved clinical trials or tissue banking studies from Children’s Oncology Group (COG) patients enrolled on ARST0331, ARST0431, D9602, D9803, and D9902 trials, as described in [2]. Those images, augmented with the metadata describing their content, were provided to the IDC team for the purposes of archival, and were converted into DICOM Whole Slide Microscopy (SM) representation [3], [4] using custom open source scripts and tools available and described here [5]. The resulting converted images were released in IDC in the RMS-Mutation-Prediction collection with the data release v16.</p> <p>To conveniently explore the data available for this dataset, please use this dashboard: <a href="https://lookerstudio.google.com/reporting/7f267400-8774-42e1-b5d1-ca11863c52a9">https://lookerstudio.google.com/reporting/7f267400-8774-42e1-b5d1-ca11863c52a9</a>.</p> <p>Notebooks demonstrating how to use this data are available here: <a href="https://github.com/ImagingDataCommons/IDC-Tutorials/tree/master/notebooks/collections_demos/rms_mutation_prediction">https://github.com/ImagingDataCommons/IDC-Tutorials/tree/master/notebooks/collections_demos/rms_mutation_prediction</a>.</p> <p>Clinical data accompanying the images is available via SQL interface in IDC BigQuery tables, see details on accessing IDC clinical data in the respective tutorial (<a href="https://github.com/ImagingDataCommons/IDC-Tutorials/blob/master/notebooks/clinical_data_intro.ipynb">https://github.com/ImagingDataCommons/IDC-Tutorials/blob/master/notebooks/clinical_data_intro.ipynb</a>).</p> <p>The images referred to by the accompanying manifests can be explored and visualized using IDC Portal here: <a href="https://portal.imaging.datacommons.cancer.gov/explore/">https://portal.imaging.datacommons.cancer.gov/explore/</a>. Direct link to open the collection is <a href="https://portal.imaging.datacommons.cancer.gov/explore/filters/?collection_id=rms_mutation_prediction">https://portal.imaging.datacommons.cancer.gov/explore/filters/?collection_id=rms_mutation_prediction</a>.</p> <p>The GCP and AWS manifests provided with this dataset record can be used to download the corresponding files from the IDC Google Cloud Storage (GCS) or Amazon S3 (AWS) buckets free of charge following the instructions available in IDC documentation here: <a href="https://learn.canceridc.dev/data/downloading-data">https://learn.canceridc.dev/data/downloading-data</a>. Specifically, you will need to install the s5cmd command line tool on your computer (see instructions at <a href="https://github.com/peak/s5cmd#installation">https://github.com/peak/s5cmd#installation</a>), and follow the manifest-specific download instructions accompanying the file list below.</p> <p>If you use the files referenced in the attached manifests, we ask you to please cite this dataset, as well as the publication describing the original dataset [2] and the publication acknowledging IDC [1].</p> <p>Specific files included in the record are:</p> <ol> <li> <p><strong><code>rms_mutation_prediction_gcs.s5cmd</code></strong>: GCS-based manifest (to download the files described in the manifest, execute this command: <code>s5cmd --no-sign-request --endpoint-url https://storage.googleapis.com run rms_mutation_prediction_gcs.s5cmd</code>)</p> </li> <li> <p><strong><code>rms_mutation_prediction_aws.s5cmd</code></strong>: AWS-based manifest (to download the files described in the manifest, execute this command: <code>s5cmd --no-sign-request --endpoint-url https://s3.amazonaws.com run rms_mutation_prediction_aws.s5cmd</code>)</p> </li> <li> <p><strong><code>rms_mutation_prediction_dcf.csv</code></strong>: Gen3-based manifest (see details in <a href="https://learn.canceridc.dev/data/organization-of-data/guids-and-uuids">https://learn.canceridc.dev/data/organization-of-data/guids-and-uuids</a>).</p> </li> </ol> <p><strong>References</strong></p> <p>[1] A. Fedorov et al., "NCI Imaging Data Commons," Cancer Res., vol. 81, no. 16, pp. 4188–4193, Aug. 2021, doi: <a href="https://dx.doi.org/10.1158/0008-5472.CAN-21-0950">10.1158/0008-5472.CAN-21-0950</a>. </p> <p>[2] D. Milewski et al., "Predicting molecular subtype and survival of rhabdomyosarcoma patients using deep learning of H&E images: A report from the Children's Oncology Group," Clin. Cancer Res., vol. 29, no. 2, pp. 364–378, Jan. 2023, doi: <a href="https://dx.doi.org/10.1158/1078-0432.CCR-22-1663">10.1158/1078-0432.CCR-22-1663</a>.</p> <p>[3] National Electrical Manufacturers Association (NEMA), "DICOM PS3.3 - Information Object Definitions: A.32.8 VL Whole Slide Microscopy Image IOD." Accessed: Aug. 11, 2023. [Online]. Available: <a href="https://dicom.nema.org/medical/dicom/current/output/html/part03.html#sect_A.32.8">https://dicom.nema.org/medical/dicom/current/output/html/part03.html#sect_A.32.8</a></p> <p>[4] M. D. Herrmann et al., "Implementing the DICOM standard for digital pathology," J. Pathol. Inform., vol. 9, no. 1, p. 37, Jan. 2018, doi: <a href="https://dx.doi.org/10.4103/jpi.jpi_42_18">10.4103/jpi.jpi_42_18</a>. </p> <p>[5] D. Clunie, A. Fedorov, and M. D. Herrmann, ImagingDataCommons/idc-wsi-conversion: Initial release. Zenodo, 2023. doi: <a href="https://dx.doi.org/10.5281/zenodo.8240154">10.5281/zenodo.8240154</a>. </p>
Ecophysiological variables of common shrub and grass species during the growing season following simulated sandblasting trials at the Jornada Experimental Range, New Mexico, USA, 2018 and 2019
In this dataset, we report ecophysiological variables of contrasting perennial grass (Bouteloua eriopoda, Sporobolus airoides, and Aristida purpurea) and shrub (Prosopis glandulosa, Atriplex canescens, and Larrea tridentata) functional groups before and after a series of simulated sandblasting events with various intensities and frequencies. We hypothesized that grass species are more susceptible to the resulting "sandblasting" (i.e., abrasive damage by wind-blown particulates) than shrubs, thus contributing to the shift from grass to shrub dominance. To test this, we conducted a wind tunnel experiment at the USDA Jornada Experimental Range in 2018 and 2019 growing seasons. Potted plants were subjected to different levels of sandblasting in a novel portable wind tunnel, and plants’ ecophysiological responses including leaf gas exchange and nighttime leaf stomatal conductance were quantified. All tested plants were then grown in benign greenhouse conditions to investigate plant recovery post sandblasting. This dataset contains data about plant biomass and height, leaf chlorophyll content, leaf gas exchange, stomatal conductance, and water use efficiency (WUE) under the experimental treatments above. This study is complete.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.